Source: Therapeutic Advances in Medical Oncology. Unidades: FMRP, FM
Subjects: BIOMARCADORES, GLICOSE, IMUNOTERAPIA, NEOPLASIAS PULMONARES
ABNT
SILVA, Saulo Brito et al. Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC. Therapeutic Advances in Medical Oncology, v. 14, p. 1-13, 2022Tradução . . Disponível em: https://doi.org/10.1177/17588359221138386. Acesso em: 18 nov. 2024.APA
Silva, S. B., Wanderley, C. W. S., Marin, J. F. G., Macedo, M. P. de, Nascimento, E. C. T. do, Antonacio, F. F., et al. (2022). Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC. Therapeutic Advances in Medical Oncology, 14, 1-13. doi:10.1177/17588359221138386NLM
Silva SB, Wanderley CWS, Marin JFG, Macedo MP de, Nascimento ECT do, Antonacio FF, Figueiredo CS, Cunha MT, Cunha F de Q, Castro Junior G de. Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC [Internet]. Therapeutic Advances in Medical Oncology. 2022 ; 14 1-13.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1177/17588359221138386Vancouver
Silva SB, Wanderley CWS, Marin JFG, Macedo MP de, Nascimento ECT do, Antonacio FF, Figueiredo CS, Cunha MT, Cunha F de Q, Castro Junior G de. Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC [Internet]. Therapeutic Advances in Medical Oncology. 2022 ; 14 1-13.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1177/17588359221138386